← Back to Search

Let's Discuss Health Website for Prostate Cancer

N/A

Recruiting

Led By Marie-Andrée Fortin, MD

Research Sponsored by Ciusss de L'Est de l'Île de Montréal

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at the end of the study, up to 1.5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to improve communication between cancer patients and their caregivers, reduce psychological distress and help patients better understand their treatments to reduce health costs and improve outcomes. #cancer #communication #caregivers #patient

Who is the study for?

This trial is for French-speaking men comfortable with the internet, diagnosed with prostate cancer, and have access to a digital device. They should be able to give informed consent and not have any severe health issues or conditions like dementia that would impair their ability to participate.

What is being tested?

The study tests the 'Let's Discuss Health' website designed to improve communication between patients with prostate cancer and their doctors, aiming to reduce psychological distress and increase treatment adherence.

What are the potential side effects?

Since this intervention involves using a website for better communication rather than medication or medical procedures, there are no direct physical side effects expected from participating in this trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at the end of the study, up to 1.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at the end of the study, up to 1.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of the study, up to 1.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Adherence to the care pathway

Dialogic rate in the exchanges during the initial patient-radiation oncologist encounter

Dialogic rate of the conversations during the end-of-treatment patient-radiation oncologist encounter

+4 more

Secondary study objectives

Change in emotional distress following the medical encounter

Frequency of themes discussed during the end-of-treatment patient-radiation oncologist encounter

Frequency of themes discussed during the initial patient-radiation oncologist encounter

+9 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Let's Discuss Health GroupExperimental Treatment1 Intervention

Patients in this group will be encouraged to prepare each of the four medical encounters targeted in the trajectory in radiation oncology using Let's Discuss Health website, which are the initial visit, the mid-treatment visit, the end-of-treatment visit and the 3-month post-treatment visit.

Group II: Usual Care GroupActive Control1 Intervention

Patients in this group will received the usual care in the radiation oncology care pathway.

Do I qualify?Apply below to find out